Regulus employs an intellectual property strategy that both protects its microRNA drug products and provides a competitive advantage in the field of microRNA therapeutics. Through a combination of product-specific, platform-based and chemistry patents, Regulus creates multiple layers of patent protection surrounding each microRNA drug product. Additionally, Regulus has intellectual property arising from our Company’s expertise in oligonucleotide manufacturing processes, drug design, bioinformatics analysis, and biological mechanisms.

Regulus has access to over 900 patents and patent applications pertaining to oligonucleotide technology useful for targeting microRNA therapeutics, and over 150 patents and patent applications directed to microRNA specific technologies.

Our technology is protected by a deep and multi-layered IP portfolio.